Breakthrough PTSD treatment achieves 68% remission rate in clinical trial
ScienceDaily
A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions.
This story was first published by ScienceDaily. The full article is on their site.
Read the full storyOpens sciencedaily.com
